We are committed to providing appropriate and equitable information disclosure to both institutional and individual investors in accordance with the principles of fair disclosure. For this reason, we refrain from responding to inquiries on an individual basis. However, we sincerely value all questions and comments received, and will utilize them, as appropriate, to improve our disclosure materials and related communications.

Regarding the progress of our business activities and pipeline developments, we will continue to provide timely and appropriate updates through press releases and periodic disclosures, to the extent that such information does not compromise the value of our business. We remain dedicated to delivering accurate and clear information, and we kindly ask for your continued understanding and support.

Questions about our company

  • What kind of business does your company engage in?

    We are a biotechnology company engaged in the research, development, and clinical testing of small‑molecule drug candidates, particularly in the oncology field.
    At present, our revenue is primarily derived from out‑licensed pipelines; however, looking ahead, we intend to pursue strategic partnerships that will enable us to advance toward in‑house manufacturing and commercialization.

  • What is the origin of your company name?

    The name Chordia is derived from the English word chord, meaning “harmony.”
    A chord consists of multiple notes resonating together to create a beautiful sound.
    Our name reflects the idea that the passion and tireless efforts of each member involved in drug discovery, combined with the support and goodwill of our external partners, come together like musical harmony—allowing us to efficiently deliver groundbreaking oncology therapies.

Questions about our stock

Questions about our financial results, business performance, and IR

  • What is your policy on shareholder returns?

    We are not currently considering dividends.
    Our priority is to advance research and development and bring our products to market as early as possible. Once we reach a stage where revenue can be generated on a continuous basis, we will reassess our approach to shareholder returns.

  • Do you disclose quarterly financial results?

    For the time being, we plan to hold earnings briefings twice a year—at mid‑term and fiscal year‑end—together with detailed presentation materials.
    From the next fiscal year onward, we will consider quarterly earnings disclosures based on the progress of our clinical programs.

  • How do you disclose information related to patents?

    Patent applications are generally published approximately 18 months after filing, and registration follows examination by the relevant authorities.
    We disclose information on patent filings, publications, and registrations in documents such as our financial results.
    However, we do not provide timely disclosure for the following reasons:

    1. Patent filings, publications, or registrations do not have a direct impact on our financial performance.
    2. Disclosing the fact that a patent has been filed may provide strategic information to competitors.

    The reference in page 2 of our financial results announcement dated July 14, 2025 (for the third quarter of the fiscal year ending August 2025), “New patent application filed in January 2024,” refers to the use‑patent application concerning the combination therapy of rogocekib with other anticancer agents, published by the World Intellectual Property Organization (WIPO) on July 17, 2025.

    We will continue to provide appropriate disclosures in accordance with this policy.

Questions about our science

  • How do you define “first in class”?

    A first‑in‑class therapy refers to an anticancer drug with an entirely novel mechanism of action.

  • Why do you focus on small molecule drugs?

    We believe small molecules offer the most advantageous modality for oral administration and carry a lower manufacturing risk due to their well‑established production processes.

  • Which pipeline are you mainly focusing on?

    For the foreseeable future, our primary focus will be on CTX‑712, our lead pipeline candidate and a CLK inhibitor.

  • What differentiates your company from competitors?

    Our team consists of seasoned drug‑discovery professionals with decades of experience.
    We were among the earliest to recognize the importance of RNA regulation stress as a new cancer hallmark and have advanced our research ahead of competitors.
    We consider this scientific leadership and development speed to be a core competitive strength.

Questions about partnership